Literature DB >> 1830663

Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation.

J M Spergel1, S Chen-Kiang.   

Abstract

An interleukin 6 (IL-6)-regulated cellular activity in HepG2 cells is found to functionally substitute for the transcriptional transactivator product of the adenovirus transforming gene E1A in transactivating E1A-dependent and E1A-responsive viral early genes. Mutant viruses deficient in E1A expression replicate in HepG2 cells. Induction with IL-6 leads to significant enhancement of synthesis of viral early E1B and E2ae mRNAs by greater than 30-fold and increases viral replication to the wild-type levels. The E1A-substituting activity activates E1A-responsive promoters in transient transfection, and this transcriptional activity is regulated by IL-6 induction. Formation of distinct protein-promoter complexes by binding of proteins in nuclear extracts prepared from HepG2 cells to the E1A-dependent E2ae promoter further supports the possibility that this activity may be a nuclear component in the IL-6 signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830663      PMCID: PMC52107          DOI: 10.1073/pnas.88.15.6472

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication.

Authors:  M M Hitt; F L Graham
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

2.  Adenovirus EIIA early promoter: transcriptional control elements and induction by the viral pre-early EIA gene, which appears to be sequence independent.

Authors:  S C Murthy; G P Bhat; B Thimmappaya
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

3.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

4.  cAMP acts in synergy with E1A protein to activate transcription of the adenovirus early genes E4 and E1A.

Authors:  D A Engel; S Hardy; T Shenk
Journal:  Genes Dev       Date:  1988-12       Impact factor: 11.361

5.  Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes.

Authors:  V Poli; R Cortese
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma.

Authors:  K Nakajima; R Wall
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

7.  Adenovirus E1A and E1B genes are regulated posttranscriptionally in human lymphoid cells.

Authors:  D J Lavery; S Chen-Kiang
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.

Authors:  K Yamasaki; T Taga; Y Hirata; H Yawata; Y Kawanishi; B Seed; T Taniguchi; T Hirano; T Kishimoto
Journal:  Science       Date:  1988-08-12       Impact factor: 47.728

9.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.

Authors:  W C Phelps; C L Yee; K Münger; P M Howley
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

10.  The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.

Authors:  P S Mattila; K S Ullman; S Fiering; E A Emmel; M McCutcheon; G R Crabtree; L A Herzenberg
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  20 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication.

Authors:  J E Nelson; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Viral vectors for vascular gene therapy.

Authors:  Lukas Fischer; Meir Preis; Anat Weisz; Belly Koren; Basil S Lewis; Moshe Y Flugelman
Journal:  Exp Clin Cardiol       Date:  2002

4.  Adenoviral-mediated gene transfer to fetal pulmonary epithelia in vitro and in vivo.

Authors:  P B McCray; K Armstrong; J Zabner; D W Miller; G A Koretzky; L Couture; J E Robillard; A E Smith; M J Welsh
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

5.  Advances in Gene Delivery Systems.

Authors:  Kenya Kamimura; Takeshi Suda; Guisheng Zhang; Dexi Liu
Journal:  Pharmaceut Med       Date:  2011-10-01

6.  Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes.

Authors:  C Balagué; F Noya; R Alemany; L T Chow; D T Curiel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Endogenous expression of E1A in human cells enhances the effect of adenovirus E3 on class I major histocompatibility complex antigen expression.

Authors:  J M Routes; B A Metz; J L Cook
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.

Authors:  P Yeh; J F Dedieu; C Orsini; E Vigne; P Denefle; M Perricaudet
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  The human topoisomerase I gene promoter is regulated by NF-IL6.

Authors:  S Heiland; R Knippers
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.